BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31437057)

  • 1. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.
    Fukuhara N; Yamamoto G; Tsujimura H; Chou T; Shibayama H; Yanai T; Shibuya K; Izutsu K
    Leuk Lymphoma; 2020 Jan; 61(1):176-180. PubMed ID: 31437057
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
    Mei M; Thomas S; Chen R
    BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
    Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
    J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
    Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
    Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
    Koga Y; Sekimizu M; Iguchi A; Kada A; Saito AM; Asada R; Mori T; Horibe K
    Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
    Song Y; Guo Y; Huang H; Li W; Ke X; Feng J; Xu W; Miao H; Kinley J; Song G; Dai Y; Wang H; Zhu J
    Expert Rev Hematol; 2021 Sep; 14(9):867-875. PubMed ID: 34275403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
    Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
    Garnock-Jones KP
    Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
    Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
    Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
    Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
    Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series.
    Contarini G; Carraro E; Lovisa F; Martire G; Lo Nigro L; Sala A; Pillon M; Mussolin L
    Br J Haematol; 2024 Jan; 204(1):352-355. PubMed ID: 37822050
    [No Abstract]   [Full Text] [Related]  

  • 14. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
    Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
    Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
    Monjanel H; Deville L; Ram-Wolff C; Venon MD; Franchi P; Benet C; de Kerviler E; Malphettes M; Thieblemont C; Brice P
    Br J Haematol; 2014 Jul; 166(2):306-8. PubMed ID: 24673542
    [No Abstract]   [Full Text] [Related]  

  • 16. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
    Broccoli A; Pellegrini C; Di Rocco A; Puccini B; Patti C; Gini G; Mannina D; Tani M; Rusconi C; Romano A; Vanazzi A; Botto B; Carlo-Stella C; Hohaus S; Musto P; Mazza P; Molica S; Corradini P; Fama A; Gaudio F; Merli M; Gravetti A; Gritti G; Arcari A; Tosi P; Liberati AM; Pinto A; Pavone V; Gherlinzoni F; Naso V; Volpetti S; Trentin L; Goldaniga MC; Bonfichi M; De Renzo A; Schiavotto C; Spina M; Storti S; Carella AM; Stefoni V; Argnani L; Zinzani PL
    Haematologica; 2017 Nov; 102(11):1931-1935. PubMed ID: 28775121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    Senter PD; Sievers EL
    Nat Biotechnol; 2012 Jul; 30(7):631-7. PubMed ID: 22781692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
    Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.
    Lai CM; Horowitz S
    Expert Rev Hematol; 2013 Aug; 6(4):361-73. PubMed ID: 23991923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.